ORMP vs TROW · rev $1.3M vs P/E 12, rev $3.76B
Oramed Pharmaceuticals Inc (ORMP) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported ORMP revenue for 2023-12-31 was $1.3M. Net income was $5.5M. Revenue was up 48.2% from 2022-12-31 to 2023-12-31. ORMP currently screens at market cap $87.2M.
Latest reported TROW revenue for 2026-06-30 was $3.76B. Net income was $1.13B. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
ORMP currently screens at market cap $87.2M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the ORMP and TROW stock pages for the full models.
Not investment advice.